Scarica l'app Stockscreener
164.65
0.92%
1.5328
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart.com
Neurocrine presents tardive dyskinesia treatment data at conference - StreetInsider
Neurocrine Biosciences director sells $210,071 in stock - Investing.com
Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan - Stock Titan
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients - PR Newswire
Neurocrine reports positive INGREZZA data for TD in patients with IDD - grafa.com
Neurocrine presents data on tardive dyskinesia treatment - Investing.com
Neurocrine presents data on tardive dyskinesia treatment By Investing.com - Investing.com Australia
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - PR Newswire
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score - ChartMill
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
Neurocrine Biosciences Inc. (NBIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
Does Neurocrine Biosciences’ (NBIX) Rare Disease Push Quietly Rewire Its Endocrine Risk-Reward Profile? - simplywall.st
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $5,770,235, According to a Recent SEC Filing - Moomoo
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance
Neurocrine Biosciences(NBIX.US) Officer Sells US$5.77 Million in Common Stock - Moomoo
Baird reiterates Neurocrine Bio stock rating on acquisition potential - Investing.com
Neurocrine (NBIX) HR chief sells 36,937 shares and exercises options in pre-set plan - Stock Titan
Neurocrine (NBIX) CMO reports RSU vesting and tax share withholding - Stock Titan
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) - Yahoo Finance
A Look At Neurocrine Biosciences (NBIX) Valuation As New CRENESSITY Data Heads To ENDO 2026 - simplywall.st
Neurocrine to present two-year Crenessity data at ENDO 2026 - Investing.com UK
NBIX Stock Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia
Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst - Quiver Quantitative
NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade
Neurocrine Biosciences Jumps 5.8% Amid Sector-Wide Rally - AlphaStreet
Two-year CRENESSITY data track CAH hormones, growth and quality of life - Stock Titan
Goldman Sachs Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $213 - Moomoo
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82 - ChartMill
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
William Blair Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating - Moomoo
Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock - Investing.com UK
Neurocrine Biosciences chief regulatory officer sells $354,321 in stock - Investing.com UK
Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock By Investing.com - Investing.com South Africa
A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Decline -- GF Value $183.77 vs Price $154.84 - GuruFocus
Neurocrine Biosciences chief regulatory officer sells $354,321 in stock By Investing.com - Investing.com Canada
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine (NASDAQ: NBIX) CRO sells 2,261 shares after option exercise - Stock Titan
24,965-share Rule 144 sale notice for Neurocrine (NASDAQ: NBIX) - Stock Titan
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com South Africa
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com
Form 144: 11,000-share sale notice tied to option exercise (NBIX) - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 21% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares By Investing.com - Investing.com Australia
Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares - Investing.com UK
0.91%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):